New pill takes on hard-to-treat blood cancers in first human trial
NCT ID NCT06146257
First seen Oct 01, 2025 · Last updated May 12, 2026 · Updated 31 times
Summary
This early-phase study tests an experimental oral drug, GLB-001, in about 48 adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that returned or didn't respond to prior therapy. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug is working against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alliance for Multispecialty Research, LLC
TERMINATEDMerriam, Kansas, 66204, United States
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center-David H. Koch Center
TERMINATEDNew York, New York, 10021, United States
-
Roswell Park Comprehensive Cancer Center
TERMINATEDBuffalo, New York, 14263, United States
-
University of California Irvine
TERMINATEDIrvine, California, 92697, United States
-
University of Kansas Medical Center Research Institute, Inc.
RECRUITINGKansas City, Kansas, 66160, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Texas M. D. Anderson Cancer Center
TERMINATEDHouston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.